{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:53:03Z","timestamp":1787590383521,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory\/relapsed B cell non-Hodgkin\u2019s lymphoma (R\/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse. We conducted a retrospective, single-arm study of 47 patients with R\/R B-NHL, and found that the combination of ASCT and CAR-T therapy improved the 3-year progression-free survival (PFS) and overall survival (OS) rates to 66.04% (95%CI: 48.311-78.928) and 72.442% (95%CI: 53.46-84.708) respectively. Furthermore, the combination therapy has no serious adverse events. Thus, ASCT combined with CAR-T cell therapy is effective against multiple subtypes of R\/R B-NHL, and can effectively prolong the long-term survival of patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1532460","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:33:21Z","timestamp":1740555201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory\/relapsed B-cell lymphoma: a single-arm clinical study"],"prefix":"10.3389","volume":"16","author":[{"given":"Danyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuenan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3532-1_12","article-title":"B cell lymphoma","volume":"1254","author":"Meng","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2017.176.issue-5","article-title":"Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"176","author":"Cencini","year":"2017","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.v10.3","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v97.12","article-title":"Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed\/refractory follicular lymphoma in China: A phase I\/II clinical trial","volume":"97","author":"Ying","year":"2022","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.286","article-title":"Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party","volume":"51","author":"Robinson","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.06.003","article-title":"Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell Malignancies","volume":"39","author":"Bao","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1706","DOI":"10.1002\/cnr2.v5.10","article-title":"CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis","volume":"5","author":"Yin","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell Malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.643404","article-title":"Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors","volume":"53","author":"Telio","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-024-01084-w","article-title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","volume":"14","author":"Shadman","year":"2024","journal-title":"Blood Cancer J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ejh.2015.94.issue-1","article-title":"Current status of haematopoietic autologous stem cell transplantation in lymphoid Malignancies: a European perspective","volume":"94","author":"Hubel","year":"2015","journal-title":"Eur J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20406207241237594","DOI":"10.1177\/20406207241237594","article-title":"Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma","volume":"15","author":"Yuan","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2900310","DOI":"10.1155\/2022\/2900310","article-title":"The autologous hematopoietic stem cells transplantation combination-based chimeric antigen receptor T-cell therapy improves outcomes of relapsed\/refractory central nervous system B-cell lymphoma","volume":"2022","author":"Xue","year":"2022","journal-title":"J Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbmt.2011.07.019","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review","volume":"18","author":"Oliansky","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008857","article-title":"Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma","volume":"12","author":"Liu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130195","article-title":"Comparation of CART19 and autologous stem-cell transplantation for refractory\/relapsed non-Hodgkin\u2019s lymphoma","volume":"5","author":"Li","year":"2019","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184452","article-title":"Clinical strategies for enhancing the efficacy of CAR T-cell therapy for hematological Malignancies","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1497736","article-title":"Case report: A novel third-generation anti-CD19\/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:33:24Z","timestamp":1740555204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1532460"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1532460","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1532460"}}